Roth Affirms Keryx (KERX) at 'Buy'; ESRD Overhang Removed

Roth Capital affirms its Buy rating and $30 price target on Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) following new regulatory news.

Analyst Joseph Pantginis commented, Yesterday, April 1, President Obama signed into law the "Protecting Access to Medicare Act of 2014". Most relevant to Keryx is the eight year delay (Jan. 1, 2024) to the implementation of including oral ESRD drugs, which includes phosphate binders, into the "bundled" payment system. Should this law had not been passed, Zerenex could have experienced early pricing pressures in the beginning of the drug's anticipated launch. These oral drugs will now continue to receive their typical reimbursement and the cost burdens will continue to be removed from dialysis centers.

Pantginis stated, We believe an important overhang has been removed. We project full approval of the drug around the June 2014 PDUFA date.

For an analyst ratings summary and ratings history on Keryx Biopharma, click here. For more ratings news on the company, click here.

Shares of Keryx Biopharma closed at $16.78 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Amazon.com (AMZN) PT Raised to $215 at UBS
• Veritex Holdings (VBTX) PT Raised to $26 at Piper Sandler